Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Improvements in survival have been made over the past two decades for childhood acute myeloid leukemia (AML), but the approximately 40% of patients who relapse continue to have poor outcomes. A combination of checkpoint-inhibitor nivolumab and azacitidine has demonstrated improvements in median surv...

Full description

Bibliographic Details
Main Authors: Anupam Verma, Yueh-Yun Chi, Jemily Malvar, Adam Lamble, Sonali Chaudhury, Archana Agarwal, Hong-Tao Li, Gangning Liang, Roy Leong, Patrick A. Brown, Joel Kaplan, Eric S. Schafer, Tamra Slone, Melinda Pauly, Bill H. Chang, Elliot Stieglitz, Alan S. Wayne, Nobuko Hijiya, Deepa Bhojwani
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Cancers
Subjects:
acute myeloid leukemia
immunotherapy
checkpoint inhibitor
DNA methylation
dose-limiting toxicity
Online Access:https://www.mdpi.com/2072-6694/16/3/496

Similar Items

Similar Items